Published in J Invest Dermatol on March 01, 2006
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17
Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet (2014) 2.08
Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol (2009) 1.30
Genetic risk factors for melanoma. Hum Genet (2009) 1.21
Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc (2008) 1.13
Telomere length and the risk of cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. PLoS One (2013) 1.07
Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. Int J Cancer (2009) 1.04
Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations. Fam Cancer (2010) 0.97
Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. J Am Acad Dermatol (2014) 0.90
Detection of Exosomal miRNAs in the Plasma of Melanoma Patients. J Clin Med (2015) 0.87
Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families. BMC Med Genet (2008) 0.84
Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer. Oncotarget (2014) 0.84
Hereditary genodermatoses with cancer predisposition. Hematol Oncol Clin North Am (2010) 0.83
Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria. Genet Med (2017) 0.78
Lack of GNAQ and GNA11 Germ-Line Mutations in Familial Melanoma Pedigrees with Uveal Melanoma or Blue Nevi. Front Oncol (2013) 0.78
Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom. Hered Cancer Clin Pract (2014) 0.78
Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev (2017) 0.75
Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet (2009) 3.89
A giant verruciform xanthoma. J Cutan Pathol (2002) 2.59
Clinical and pathological features of pachyonychia congenita. J Investig Dermatol Symp Proc (2005) 2.45
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res (2006) 2.40
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol (2007) 2.19
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet (2012) 2.18
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17
Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo. J Invest Dermatol (2007) 2.11
The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol (2002) 2.10
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet (2005) 1.96
A variant of AESOP syndrome (adenopathy and extensive skin patch overlying a plasmacytoma) in a malignant blue-cell tumor. Arch Dermatol (2012) 1.92
Shared predispositions of parkinsonism and cancer: a population-based pedigree-linked study. Arch Neurol (2012) 1.87
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet (2013) 1.85
Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet (2006) 1.70
Reflectance spectrophotometer: the dermatologists' sphygmomanometer for skin phototyping? J Invest Dermatol (2008) 1.65
Population-based family history-specific risks for colorectal cancer: a constellation approach. Gastroenterology (2009) 1.61
Identification of excess clustering of coronary heart diseases among extended pedigrees in a genealogical population database. Am Heart J (2006) 1.60
Meta association of colorectal cancer confirms risk alleles at 8q24 and 18q21. Cancer Epidemiol Biomarkers Prev (2009) 1.60
Evidence for an inherited predisposition to lumbar disc disease. J Bone Joint Surg Am (2011) 1.53
Keratin K6c mutations cause focal palmoplantar keratoderma. J Invest Dermatol (2009) 1.51
Comparative analysis of total body and dermatoscopic photographic monitoring of nevi in similar patient populations at risk for cutaneous melanoma. Dermatol Surg (2010) 1.46
Single-nucleotide-specific siRNA targeting in a dominant-negative skin model. J Invest Dermatol (2007) 1.46
Clinical genetic testing for familial melanoma in Italy: a cooperative study. J Am Acad Dermatol (2009) 1.45
Longitudinal assessment of the nevus phenotype in a melanoma kindred. J Invest Dermatol (2004) 1.44
Empiric evidence for a genetic contribution to predisposition to surgical site infection. Wound Repair Regen (2013) 1.43
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol (2011) 1.39
Lepromatous leprosy and reversal reaction in a Micronesian immigrant. Int J Dermatol (2003) 1.38
Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol (2005) 1.35
The genetic basis of pachyonychia congenita. J Investig Dermatol Symp Proc (2005) 1.34
Strongly positive tissue transglutaminase antibodies are associated with Marsh 3 histopathology in adult and pediatric celiac disease. J Clin Gastroenterol (2008) 1.29
Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev (2009) 1.29
A genealogical assessment of heritable predisposition to asthma mortality. Am J Respir Crit Care Med (2007) 1.25
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer (2010) 1.24
CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. Cancer Epidemiol Biomarkers Prev (2008) 1.22
Evidence for an inherited predisposition contributing to the risk for rotator cuff disease. J Bone Joint Surg Am (2009) 1.21
Predictors of sun protection behaviors and severe sunburn in an international online study. Cancer Epidemiol Biomarkers Prev (2010) 1.21
Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. J Clin Oncol (2003) 1.20
Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Hum Mol Genet (2007) 1.20
Lobular breast cancer: excess familiality observed in the Utah Population Database. Int J Cancer (2005) 1.20
Co-occurrence of celiac disease and other autoimmune diseases in celiacs and their first-degree relatives. J Autoimmun (2008) 1.20
Significant evidence for a heritable contribution to cancer predisposition: a review of cancer familiality by site. BMC Cancer (2012) 1.18
Extracolonic cancers associated with hereditary nonpolyposis colorectal cancer in the Utah Population Database. Am J Gastroenterol (2006) 1.17
Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol (2006) 1.17
Significant linkage evidence for a predisposition gene for pelvic floor disorders on chromosome 9q21. Am J Hum Genet (2009) 1.16
Localization of a prostate cancer predisposition gene to an 880-kb region on chromosome 22q12.3 in Utah high-risk pedigrees. Cancer Res (2006) 1.16
A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. J Am Acad Dermatol (2012) 1.15
Comparison of compliance for colorectal cancer screening and surveillance by colonoscopy based on risk. Genet Med (2011) 1.13
Correlation of duodenal histology with tissue transglutaminase and endomysial antibody levels in pediatric celiac disease. Clin Gastroenterol Hepatol (2007) 1.13
UVB-induced apoptosis drives clonal expansion during skin tumor development. Carcinogenesis (2004) 1.13
Genotype-phenotype correlations among pachyonychia congenita patients with K16 mutations. J Invest Dermatol (2010) 1.13
Treatment of pachyonychia congenita. J Investig Dermatol Symp Proc (2005) 1.13
Androgen receptor expression patterns in Becker's nevi: an immunohistochemical study. J Am Acad Dermatol (2008) 1.12
A role for XRCC2 gene polymorphisms in breast cancer risk and survival. J Med Genet (2011) 1.10
Genetic variants in XRCC2: new insights into colorectal cancer tumorigenesis. Cancer Epidemiol Biomarkers Prev (2009) 1.10
Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice. Cancer Res (2007) 1.10
Prevalence of celiac disease among relatives of sib pairs with celiac disease in U.S. families. Am J Gastroenterol (2003) 1.09
Genome-wide linkage analyses of extended Utah pedigrees identifies loci that influence recurrent, early-onset major depression and anxiety disorders. Am J Med Genet B Neuropsychiatr Genet (2005) 1.08
Familiality in brain tumors. Neurology (2008) 1.06
A comprehensive survey of cancer risks in extended families. Genet Med (2012) 1.06
Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol (2005) 1.04
Melanoma cells express elevated levels of phosphorylated histone H2AX foci. J Invest Dermatol (2005) 1.04
Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi. J Am Acad Dermatol (2009) 1.03
IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis and pediatric celiac disease. J Invest Dermatol (2009) 1.03
Evidence for a heritable component in death resulting from aortic and mitral valve diseases. Circulation (2004) 1.02
A spectrum of mutations in keratins K6a, K16 and K17 causing pachyonychia congenita. J Dermatol Sci (2007) 1.00
Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. Cancer Res (2003) 1.00
Clinical germline genetic testing for melanoma. Lancet Oncol (2004) 1.00
Use of self-delivery siRNAs to inhibit gene expression in an organotypic pachyonychia congenita model. J Invest Dermatol (2011) 1.00
Melanoma genetic counseling and test reporting improve screening adherence among unaffected carriers 2 years later. Cancer Epidemiol Biomarkers Prev (2013) 0.99
A large mutational study in pachyonychia congenita. J Invest Dermatol (2011) 0.99
N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice. Clin Cancer Res (2007) 0.98
Genetic testing for hereditary melanoma and pancreatic cancer: a longitudinal study of psychological outcome. Psychooncology (2011) 0.98
The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression. Epigenetics (2011) 0.97
Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol (2002) 0.97
Proliferation, apoptosis, and survivin expression in keratinocytic neoplasms and hyperplasias. Am J Dermatopathol (2004) 0.97
A population-based description of familial clustering of pancreatic cancer. Clin Gastroenterol Hepatol (2010) 0.97
Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. J Cutan Pathol (2015) 0.96
Characterization of linkage disequilibrium structure, mutation history, and tagging SNPs, and their use in association analyses: ELAC2 and familial early-onset prostate cancer. Genet Epidemiol (2005) 0.96
Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention. Clin Cancer Res (2009) 0.96
Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction. Cancer (2005) 0.96
Statistical recombinant mapping in extended high-risk Utah pedigrees narrows the 8q24 prostate cancer locus to 2.0 Mb. Prostate (2007) 0.95
Pancreatic carcinoma surveillance in patients with familial melanoma. Arch Dermatol (2003) 0.95
Familial myeloma. N Engl J Med (2008) 0.94
Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling. J Am Acad Dermatol (2009) 0.94
Fine-mapping CASP8 risk variants in breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 0.94